MIN-202
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
[5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone
|
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1293281-49-8  |
| ATC code | None |
| PubChem | CID 67116280 |
| Chemical data | |
| Formula | C21H22FN7O |
| Molar mass | 407.443 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
MIN-202 (also known as JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).[1][2][3] As of December 2015, it is in phase II clinical trials for both insomnia and MDD.[2][4][5]
See also[edit]
References[edit]
- ^ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.
- ^ a b Zisapel, Nava (2014). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs: 1–11. doi:10.1517/13543784.2015.987340. ISSN 1354-3784.
- ^ Cristoph Boss; Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012.
- ^ "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
- ^ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.
Further reading[edit]
- Discovery of JNJ-42847922, a Selective Orexin-2 Antagonist for the Treatment of Insomnia Disorder (see MEDI 244)
- Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia (page A3)[dead link]
External links[edit]
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
